Lentiviral Vectors Market Size to Exceed USD 1,345.3 Mn by 2032

The Lentiviral Vectors Market, estimated at USD 410.0 Mn in 2025, is expected to exhibit a CAGR of 18.5% and reach USD 1,345.3 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

The key market players are focused on adopting growth strategies such as partnership as well as acquisition, and increasing research & development activities by market players which will drive the global lentiviral vectors market during the forecast period. For instance, on May 18, 2025, Orogenesis, Inc., a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its U.S.-based point-of-care (POCare) services subsidiary, Morgenesis LLC, a biotechnology company, signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors. The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s (Good Manufacturing practices) GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).

Global Lentiviral Vectors Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global lentiviral vectors market as on the growth of the viral vector manufacturing market. According to the WHO, global COVID-19 Vaccination- Strategic Vision for 2025, there are at least 17 vaccines in use. For instance, in November 2025, 12.88 billion doses were administered, and another 400 and more vaccine candidates were in clinical and preclinical development. Two viral vector vaccines have been authorized for emergency use in many countries for COVID-19, as of January 2025, according to the Viral Vector Vaccines segment published by the Infectious Diseases Society of America. Moreover, various companies are launching their products and are involved in various partnerships, collaborations, and other developments which are expected to positively impact the market.

Global Lentiviral Vectors Market: Key Developments

In December 2025, Oxford Biomedica plc, a gene and cell therapy company specialising in the development of gene-based medicines, announced that it has agreed an extension and update to its commercial supply Agreement with Novartis for the manufacture of lentiviral vectors for several Novartis AG (chimeric antigen receptors-therapy) CAR-T products.

In June 2025, Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant lentiviral vector production facility. The investment builds on Genezen’s expertise in lentiviral and retroviral vector production and early-phase development of cell therapy products, so the company can help current and future clients initiate and continue to supply early phase clinical trials.

In January 2025, ASC Therapeutics, a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences, a provider of vector products and services used in gene therapy. Vigene will provide ASC Therapeutics with access to (Good Manufacturing Practices) GMP manufacturing including viral vectors and plasmid DNA for its hemophilia A gene therapy clinical program, as well as a manufacturing platform for future gene therapy programs.

Browse 32 Market Data Tables and 26 Figures spread through 220 Pages and in-depth TOC on “Global Lentiviral Vectors Market”- Forecast to 2032, Global Lentiviral Vectors Market, By Product Type (1st-generation, 2nd-generation, and 3rd-generation), By Indication (HIV, β-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, and Wiskott-Aldrich Syndrome), By End User (Hospitals, Clinics, and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/lentiviral-vectors-market-4068

Key Takeaways of the Global Lentiviral Vectors Market:

• The global lentiviral vectors market is expected to exhibit a CAGR of 18.5% during the forecast period and this is attributed due to the increase in the collaboration agreement by the market key players in the global lentiviral vectors market. For instance, in August 2025, Boehringer Ingelheim International GmbH, the U.K.-based Cystic Fibrosis Gene Therapy Consortium (GTC)—consisting of Imperial College London and the Universities of Oxford and Edinburgh—Imperial Innovations, and Oxford BioMedica, a gene and cell therapy company specialising in the development of gene-based medicines, announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). The new partnership brings together the academic partners’ expertise in developing gene therapy for CF and Oxford BioMedica’s expertise in manufacturing lentiviral vector-based therapies with Boehringer Ingelheim’s capabilities in drug discovery and the clinical development of novel breakthrough therapeutic agents.
• Among End User, the research insititutes segment is expected to growth in the global lentiviral vectors market over the forecast period, owing to the rise in research & development by the key market players and increasing novel treatment. For instance, in June 2025, GenScript, a biotechnology company that provides life science research and applications solutions, announced the launch of its Research Lentiviral Vector Packaging Service for cell line development, gene editing, and drug discovery. The service enables scientists to package their genetic material of choice using GenScript's proprietary platform to ensure consistent production of functional and intact viruses.
• Among Product Type, the 1st-generation segment is expected to hold a dominant position in the global lentiviral vectors market during the forecast period and this is attributed as it is used in the treatment of various type of diseases such as diabetes mellitus, murine haemophilia a, prostate cancer, chronic granulomatous disease, and vascular diseases. 1st-generation lentivirals vectors contains a significant portion of the HIV portion, including the gag and pol genes as well as several assitional viral proteins. So, key players are focusing on strategies such as collaboration as well as acquisition for the global lentiviral vectors market growth. For instance, in February 2025, Ensoma, Inc., a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications, announced it has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited. The agreement grants Takeda an exclusive worldwide license to Ensoma’s Engenious vectors for up to five rare disease indications.
• Major players operating in the global lentiviral vectors market include Thermo Fisher Scientific Inc., Sirion-Biotech GmbH (Revvity), Vector Biolabs, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological, Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, bluebird bio, Inc., Cellomics Technology, LLC., Virica Biotech, Oxford Biomedica, and ANDELYN BIOSCIENCES.